Program
HRS8179
A development code. Also written as “HRS8179 injection”.
Its studies are mostly in Brain Edema, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 21 open or running | phase 3since Dec 10, 2024 | Dec 27, 2022 | Jun 2027phase 3 · NCT06732648 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 27, 2022First study: phase 2 study in Brain EdemaFirst studyNCT05690711 · 40 enrolled · China
- Dec 10, 2024Phase 3 study in Severe Cerebral Edema Following Large Hemispheric InfarctionNCT06732648 · 725 planned · China
Ahead
- Jun 2027Primary completion: phase 3 study in Severe Cerebral Edema Following Large Hemispheric InfarctionNCT06732648
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06732648Severe Cerebral Edema Following Large Hemispheric Infarction · China | 3 | Recruiting | Jun 2027 | 725 |
| NCT05690711Brain Edema · China | 2 | Completed | Dec 5, 2023 | 40 |
How it is read
Names in the registry
- “HRS8179 injection”, 1 entry
- “HRS8179”, 1 entry
Codes read as this program: HRS8179.
Conditions, from the studies’ own filings
- Brain Edema, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.